Biomarker, Crohn Disease, Diagnosis, Interleukin 12, Interleukin 23
Conditions
Brief summary
This study aims to evaluate the role of Interleukin (IL)-12 and IL-23 as potential biomarkers in the diagnosis of early Crohn's disease.
Detailed description
Crohn's disease (CD) is characterized by periods of remission and relapse, with symptoms ranging from abdominal pain and diarrhea to severe complications such as fistulas and intestinal obstruction. Interleukins (ILs) are known clusters of cytokines that regulate the proliferation, development, and activation of immune cells. IL-12 is predominantly a pro-inflammatory cytokine secreted by antigen-presenting cells (APC) in response to sensing of microbial components by Toll-like receptors. Another member of this family, IL-23 is also produced by DCs and macrophages after toll-like receptors (TLRs) engagement.
Interventions
PROCEDUREImmunohistochemistry procedure
Briefly, all slides will be rehydrated, and antigen retrieval will be performed using sodium citrate (pH = 6.0) in a pressure cooker (EDTA buffer, pH = 8.4). All slides will be blocked with endogenous peroxidase with 3% hydrogen peroxide and blocked non-specific protein with 2.5% bovine serum albumin in phosphate-buffered saline. If the result shows non-specific ileitis, immunohistochemical staining for IL-12 and IL-23 will be performed using sandwich enzyme-linked immunosorbent assays (ELISA).
Sponsors
Tanta University
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age from 18 to 65 years. * Both sexes. * Patients who are suspected of having Crohn's disease clinically and by colonoscopy (like ulcers, fistulas, or skip lesions). * Non-specific ileitis by histopathology.
Exclusion criteria
* Patients with no pathological samples through colonoscopy. * History of other significant gastrointestinal diseases (e.g., colon cancer, ischemic bowel disease). * Immunosuppressive therapy or biologic agents at the time of study. * Previous abdominal surgeries.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity of IL-23 to predict Crohn's disease | 6 months after procedure | Sensitivity of IL-23 to predict Crohn's disease will be recorded. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity of IL-12 to predict Crohn's disease | 6 months after procedure | Sensitivity of IL-12 to predict Crohn's disease will be recorded. |
Countries
Egypt
Outcome results
None listed